GLUE
Price
$4.60
Change
-$0.06 (-1.29%)
Updated
Jun 27 closing price
Capitalization
282.95M
39 days until earnings call
GUTS
Price
$1.64
Change
-$0.10 (-5.75%)
Updated
Jun 27 closing price
Capitalization
80.32M
44 days until earnings call
Interact to see
Advertisement

GLUE vs GUTS

Header iconGLUE vs GUTS Comparison
Open Charts GLUE vs GUTSBanner chart's image
Monte Rosa Therapeutics
Price$4.60
Change-$0.06 (-1.29%)
Volume$942.63K
Capitalization282.95M
Fractyl Health
Price$1.64
Change-$0.10 (-5.75%)
Volume$4.2M
Capitalization80.32M
GLUE vs GUTS Comparison Chart in %
Loading...
GLUE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GUTS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GLUE vs. GUTS commentary
Jun 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GLUE is a Buy and GUTS is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 30, 2025
Stock price -- (GLUE: $4.60 vs. GUTS: $1.64)
Brand notoriety: GLUE and GUTS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GLUE: 213% vs. GUTS: 784%
Market capitalization -- GLUE: $282.95M vs. GUTS: $80.32M
GLUE [@Biotechnology] is valued at $282.95M. GUTS’s [@Biotechnology] market capitalization is $80.32M. The market cap for tickers in the [@Biotechnology] industry ranges from $304.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GLUE’s FA Score shows that 0 FA rating(s) are green whileGUTS’s FA Score has 0 green FA rating(s).

  • GLUE’s FA Score: 0 green, 5 red.
  • GUTS’s FA Score: 0 green, 5 red.
According to our system of comparison, GLUE is a better buy in the long-term than GUTS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GLUE’s TA Score shows that 4 TA indicator(s) are bullish while GUTS’s TA Score has 2 bullish TA indicator(s).

  • GLUE’s TA Score: 4 bullish, 5 bearish.
  • GUTS’s TA Score: 2 bullish, 6 bearish.
According to our system of comparison, GLUE is a better buy in the short-term than GUTS.

Price Growth

GLUE (@Biotechnology) experienced а -0.65% price change this week, while GUTS (@Biotechnology) price change was -23.36% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

GLUE is expected to report earnings on Aug 07, 2025.

GUTS is expected to report earnings on Aug 13, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GLUE($283M) has a higher market cap than GUTS($80.3M). GUTS YTD gains are higher at: -20.388 vs. GLUE (-33.718). GLUE has higher annual earnings (EBITDA): 6.14M vs. GUTS (-95.83M). GLUE has more cash in the bank: 326M vs. GUTS (42.1M). GLUE has less debt than GUTS: GLUE (41.9M) vs GUTS (61.4M). GLUE has higher revenues than GUTS: GLUE (159M) vs GUTS (60K).
GLUEGUTSGLUE / GUTS
Capitalization283M80.3M352%
EBITDA6.14M-95.83M-6%
Gain YTD-33.718-20.388165%
P/E Ratio38.25N/A-
Revenue159M60K265,000%
Total Cash326M42.1M774%
Total Debt41.9M61.4M68%
TECHNICAL ANALYSIS
Technical Analysis
GLUEGUTS
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
87%
Bullish Trend 3 days ago
90%
Momentum
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
MACD
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
86%
Bearish Trend 3 days ago
90%
Advances
ODDS (%)
N/A
N/A
Declines
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 12 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
GLUE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GUTS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
KREVF0.69N/A
N/A
Keppel REIT
BKOR21.76N/A
N/A
Oak Ridge Financial Services, Inc.
SCVPY4.90N/A
N/A
Siam Cement Public Co. Ltd.
FRFFF18.29N/A
N/A
Fairfax Financial Holdings Ltd.
THNCF1.50N/A
N/A
Thinkific Labs Inc.

GLUE and

Correlation & Price change

A.I.dvisor indicates that over the last year, GLUE has been loosely correlated with EYPT. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if GLUE jumps, then EYPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GLUE
1D Price
Change %
GLUE100%
-1.29%
EYPT - GLUE
47%
Loosely correlated
-7.04%
IMNM - GLUE
44%
Loosely correlated
-0.23%
ATXS - GLUE
43%
Loosely correlated
N/A
CRSP - GLUE
43%
Loosely correlated
N/A
RXRX - GLUE
42%
Loosely correlated
-6.85%
More

GUTS and

Correlation & Price change

A.I.dvisor tells us that GUTS and IPSC have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that GUTS and IPSC's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GUTS
1D Price
Change %
GUTS100%
-5.75%
IPSC - GUTS
33%
Poorly correlated
-5.74%
ADPT - GUTS
33%
Poorly correlated
-3.04%
SCPH - GUTS
33%
Poorly correlated
-2.76%
GLUE - GUTS
33%
Poorly correlated
-1.29%
RCKT - GUTS
32%
Poorly correlated
-2.90%
More